Company: FVN
Filing Date: 2025-04-14
Form Type: DRS/A
Source: 0001829126-25-002616
Chunk: 140

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-04-14
Form: DRS/A
Chunk 140
---
.

<div align='center'>75</div>

We have approved PRC patent applications in our portfolio and may have future pending patent, trademark and other intellectual property rights applications; however, we cannot predict:

| ● | If and when patents will issue based on our applications;                                                                                                                                  |
| ● | The scope of protection of any patent issuing based on our applications;                                                                                                                   |
| ● | The degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents; |
| ● | Whether any of our intellectual property will provide any competitive advantage;                                                                                                           |
| ● | Whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications;                                                                |
| ● | Whether we will need to initiate or defend litigation or administrative proceedings to enforce and/or defend our patent rights, which may be costly whether we win or lose; or             |
| ● | Whether the patent applications that we own or may in-license will result in issued patents with claims that cover our product candidates or uses thereof in any countries.                |

<div align='center'>76</div>

Risks Related to New VIWO’s Status as a Foreign Private Issuer

New VIWO will convert to foreign private issuer status within the meaning of the rules under the Exchange Act upon the first available determination date, and, as such, New VIWO will be exempt from certain provisions applicable to United States domestic public companies. New VIWO may lose its status as a foreign private issuer in the future, causing it to incur substantial costs, time and resources.

Because New VIWO will convert to foreign private issuer under the Exchange Act upon the first relevant determination date following the consummation of the Business Combination, New VIWO is exempt from certain provisions of the securities rules and regulations in the United States that are applicable to U.S. domestic issuers, including: (i) the rules under the Exchange Act requiring the filing of quarterly reports on Form 10-Q or current reports on Form 8-K with the SEC; (ii) the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; (iii) the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iv) the selective disclosure rules by issuers of material non-public information under Regulation FD.

New